64 related articles for article (PubMed ID: 31151915)
1. A Cost Analysis of Phosphodiesterase Type 5 Inhibitors in the United States.
Nabavizadeh B; Nguyen A; Li D; van Meijgaard J; Breyer BN
Urology; 2024 Jan; 183():127-133. PubMed ID: 37951363
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase 5 inhibition as a therapeutic target for ischemic stroke: A systematic review of preclinical studies.
Ölmestig JNE; Marlet IR; Hainsworth AH; Kruuse C
Cell Signal; 2017 Oct; 38():39-48. PubMed ID: 28648945
[TBL] [Abstract][Full Text] [Related]
3. A Comparison of Pharmaceutical Prices for Generic Erectile Dysfunction and Benign Prostatic Hyperplasia Medication in 2 Socioeconomically Disparate New York City Neighborhoods.
Levy M; Garden EB; Tomer N; Al-Alao O; Small AC; Palese MA
Urol Pract; 2022 Jan; 9(1):25-31. PubMed ID: 37145565
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase type 5 inhibitors as treatment for erectile dysfunction: a webinar-based poll unveiling perceptions of healthcare professionals.
Moazin MS; Baazeem A; Al-Bakri A; Dayel AA; Amir A; Sifri SA; Reda M; Bashraheel F; Alfakhri A; Hamdy Y; Elshaer F
J Comp Eff Res; 2024 May; ():e230155. PubMed ID: 38775343
[No Abstract] [Full Text] [Related]
5. Evaluation of Serum/Urine Genomic and Metabolomic Profiles to Improve the Adherence to Sildenafil Therapy in Patients with Erectile Dysfunction.
Rocca MS; Vignoli A; Tenori L; Ghezzi M; De Rocco Ponce M; Vatsellas G; Thanos D; Padrini R; Foresta C; De Toni L
Front Pharmacol; 2020; 11():602369. PubMed ID: 33536912
[TBL] [Abstract][Full Text] [Related]
6. Association Between Common Urologic Medications and Onset of Alzheimer's Disease and Related Dementias in Men With Prostate Cancer Managed by Different Primary Treatment Modalities.
Braun AE; Cowan JE; Hampson LA; Broering JM; Suskind AM; Carroll PR
Urology; 2023 Dec; 182():161-167. PubMed ID: 37689247
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction.
Dorsey P; Keel C; Klavens M; Hellstrom WJ
Expert Opin Pharmacother; 2010 May; 11(7):1109-22. PubMed ID: 20402554
[TBL] [Abstract][Full Text] [Related]
8. First-generation phosphodiesterase type 5 inhibitors dropout: a comprehensive review and meta-analysis.
Corona G; Rastrelli G; Burri A; Serra E; Gianfrilli D; Mannucci E; Jannini EA; Maggi M
Andrology; 2016 Nov; 4(6):1002-1009. PubMed ID: 27636710
[TBL] [Abstract][Full Text] [Related]
9. A cost-utility analysis of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction.
Hansen SA; Aas E; Solli O
Eur J Health Econ; 2020 Feb; 21(1):73-84. PubMed ID: 31512069
[TBL] [Abstract][Full Text] [Related]
10. Variability in Prices for Erectile Dysfunction Medications-Are All Pharmacies the Same?
Mishra K; Bukavina L; Mahran A; Bobrow A; Buzzy CA; Jain N; Gnessin E; Loeb A; Ponsky LE
J Sex Med; 2018 Dec; 15(12):1785-1791. PubMed ID: 30527054
[TBL] [Abstract][Full Text] [Related]
11. A 6 month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Latin American men with erectile dysfunction.
Rubio-Aurioles E; Reyes LA; Borregales L; Cairoli C; Sorsaburu S
Curr Med Res Opin; 2013 Jun; 29(6):695-706. PubMed ID: 23540375
[TBL] [Abstract][Full Text] [Related]
12. Risk of Melanoma With Phosphodiesterase Type 5 Inhibitor Use Among Patients With Erectile Dysfunction, Pulmonary Hypertension, and Lower Urinary Tract Symptoms.
Shkolyar E; Li S; Tang J; Eisenberg ML
J Sex Med; 2018 Jul; 15(7):982-989. PubMed ID: 29884444
[TBL] [Abstract][Full Text] [Related]
13. An Evaluation of a Clinical Care Pathway for the Management of Men With Nonorganic Erectile Dysfunction.
Jenkins LC; Hall M; Deveci S; Guhring P; Parker M; Nelson CJ; Mulhall JP
J Sex Med; 2019 Oct; 16(10):1541-1546. PubMed ID: 31444103
[TBL] [Abstract][Full Text] [Related]
14. [Do phosphodiesterase type 5 inhibitors generics enhance discontinuation due to price with patients suffering from erectile dysfunction?].
Baydaroglu E; Eschwège P; Hubert J; El Osta R
Prog Urol; 2019; 29(6):326-331. PubMed ID: 31151915
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
